Global Health Ltd Q1 FY26 – 300 Beds Added, 3,000 Beds Promised, and P/E That Needs Its Own ICU
1. At a Glance
Global Health Ltd, better known by its fancy Medanta brand, has decided that India needs hospitals the way Bollywood needs remakes—more, bigger, and everywhere. With five operational hospitals (Gurugram, Lucknow, Patna, Indore, Ranchi) and a shiny new 550-bed facility launched in Noida (300 operational as of Sept 1, 2025), the company is on a bed-expansion spree. Current stock trades at ₹1,330 with a market cap of ₹35,736 Cr and a P/E of 62.6—basically, the valuation is sicker than most of their patients.
2. Introduction
Picture this: India’s healthcare scene is a cocktail of overworked government hospitals and overpriced private setups where the bill sometimes looks like your kid’s IIT donation receipt. Enter Medanta, rolling in with its “doctor-led” management model, making healthcare look like a corporate boardroom drama with scalpels instead of balance sheets.
Global Health Ltd is clearly riding the healthcare demand wave—aging population, lifestyle diseases, medical tourism, and Indians who believe Google + turmeric milk can cure cancer until the 11th hour. Their pitch is simple: “We’ll give you the heart surgery, robotic arm, and Da Vinci systems, but don’t expect the bill to come with a discount coupon.”
Revenue growth is healthy (15% YoY), profit growth even healthier (49% QoQ in the latest quarter), and margins at 24% are fatter than a Delhi wedding buffet. But wait—capex commitments of ₹2,800 Cr over five years for ~2,900 new beds will test whether this expansion is visionary… or vanity.
So, should one treat Medanta as the Apollo 2.0, or is this just Fortis with better marketing?
3. Business Model – WTF Do They Even Do?
Global Health Ltd basically monetizes sickness. Their hospitals are multi-specialty cash registers that charge for everything from heart transplants to “preventive” health checks (aka charging healthy people for proving they’re not sick).
Core Specialties: Cardiology (21% revenue), Cancer (14%), Neuro (12%), Digestive (12%). Basically, if it can break, block, or grow uncontrollably in your body—they’ll bill it.
Expansion Strategy: New hospitals in Noida, Mumbai, Guwahati, and South Delhi, plus plans for Pitampura and medical colleges. Translation: “We want to bill you in every metro corner possible.”
Doctor-Led Governance: Fancy way of saying surgeons run the show, not MBAs. Because who better to make decisions about ₹1,200 Cr hospital projects than someone who spends their day cracking open chests?
The company thrives on ARPOB (Average Revenue Per Occupied Bed) of ₹63,023. In simpler terms: each patient bed prints money faster than PayTM IPO marketing brochures.
Question for you: if hospitals are this profitable, why are most Indian families still crowd-funding surgeries on Ketto?
4. Financials Overview
Metric
Latest Qtr (Jun’25)
YoY Qtr (Jun’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue
1,031 Cr
861 Cr
931 Cr
19.7%
10.7%
EBITDA
247 Cr
186 Cr
225 Cr
32.8%
9.8%
PAT
159 Cr
106 Cr
101 Cr
50.0%
57.4%
EPS (₹)
5.92
3.96
3.78
49.5%
56.6%
Commentary: Medanta’s earnings are behaving like an AI stock—high growth, high margin, but also high P/E that could cause palpitations. Annualised EPS comes to ₹23.7, putting forward P/E at ~56x. That’s not a valuation, that’s a diagnostic report.
5. Valuation Discussion – Fair Value Range
P/E Method: EPS (TTM) ₹19.9 × Industry P/E (58.6) → ₹1,165. On forward EPS (₹23.7) × 58.6 → ₹1,388.
EV/EBITDA Method: EV/EBITDA at 34.8 vs industry ~30. Normalising: 30× FY25 EBITDA (₹937 Cr) = ~₹28,110 Cr EV. Add debt/cash → ₹29,000 Cr → Per share ~₹1,080.
DCF (rough): Assuming 15% growth for 5 years, terminal 8%, discount 11% → Fair range ~₹1,150–1,350.
Fair Value Range: ₹1,080 – ₹1,380 Disclaimer: This range is purely for educational purposes. Not investment advice. If you treat this like a stock tip, please also treat Panadol as a cure for heartbreak.
